Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02290340
Other study ID # D5290C00002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 13, 2015
Est. completion date September 28, 2016

Study information

Verified date September 2018
Source MedImmune LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm infants.


Description:

This Phase 1b/2a study will be a dose-escalation design to begin data collection on PK and safety in children. The population to be enrolled is healthy preterm infants born between 32 weeks 0 days and 34 weeks 6 days gestation who would not receive RSV prophylaxis based on the American Academy of Pediatrics (AAP) or other local guidelines. These subjects will not be receiving palivizumab, allowing for a placebo comparator group to begin collecting data on incidence rates of RSV medically attended lower respiratory illness (MA-LRI) and efficacy. Enrollment is planned at approximately 20 sites in the USA, Chile, and South Africa.


Recruitment information / eligibility

Status Completed
Enrollment 151
Est. completion date September 28, 2016
Est. primary completion date September 28, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 12 Months
Eligibility Key Inclusion Criteria:

- Healthy infants born between 32 weeks 0 days and 34 weeks 6 days gestational age

- Infants who are entering their first RSV season at the time of screening

Key Exclusion Criteria:

- Gestational age < 32 weeks 0 days and >34 weeks 6 days

- Meets AAP or other local criteria to receive commercial palivizumab

- Any fever (= 100.4°F [= 38.0°C], regardless of route) or lower respiratory illness within 7 days prior to randomization

- Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization

- Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection

- Receipt of palivizumab or any RSV vaccine, including maternal RSV vaccination

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Participants will receive placebo intramuscularly.
MEDI8897 10 mg
Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
MEDI8897 25 mg
Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
MEDI8897 50 mg
Participants will receive a single dose of MEDI8897 50 mg intramuscularly.

Locations

Country Name City State
Chile Research Site Santiago
Chile Research Site Valdivia
South Africa Research Site Cape Town
South Africa Research Site East London
South Africa Research Site Johannesburg
South Africa Research Site Pretoria
United States Research Site Anaheim California
United States Research Site Charleston South Carolina
United States Research Site Cleveland Ohio
United States Research Site Marshfield Wisconsin
United States Research Site Ontario California
United States Research Site Saint George Utah
United States Research Site Syracuse New York

Sponsors (1)

Lead Sponsor Collaborator
MedImmune LLC

Countries where clinical trial is conducted

United States,  Chile,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity of a participant who received MEDI8897. TEAEs and TESAEs were the events that occurred between administration of study drug (Day 1) and Day 361 that were absent before treatment or that worsened relative to pre-treatment state. From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)
Primary Number of Participants With Treatment-Emergent Adverse Events of Special Interest An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator (that is, within 24 hrs of knowledge of the event) to the sponsor. The AESIs for this study were hepatic function abnormality meeting the definition of Hy's law, hypersensitivity reactions including anaphylaxis, immune complex disease, and thrombocytopenia. Treatment-emergent AESIs were collected from the time of dosing until Day 361 post-dose. From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)
Primary Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events Laboratory abnormalities determined by the investigator to be clinically significant that occurred after study drug dosing through 151 days post-dose that were absent before treatment or that worsened relative to pre-treatment state were reported as TEAEs. Laboratory evaluations (haematology and serum chemistry) of blood samples were performed. From Study Drug Administration (Day 1) Through the Follow-up Period (Day 151)
Secondary Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897 The Tmax defined as time at which maximum observed concentration of MEDI8897 (Cmax) was observed. Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Secondary Maximum Observed Serum Concentration (Cmax) of MEDI8897 The Cmax is the maximum observed serum concentration of MEDI8897. Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Secondary Area Under the Concentration-Time Curve From Day 1 to Day 151 (AUC [1-151]) of MEDI8897 Area under the concentration-time curve of the MEDI8897 in serum over the time interval from day 1 to day 151 (AUC1-151). Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), and 150 (± 7) Post-dose
Secondary Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI8897 The pharmacokinetic (PK) parameter AUC (0-infinity) was estimated based on the serum concentrations of MEDI8897. Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Secondary Terminal Elimination Half Life (t1/2) of MEDI8897 Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum. Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Secondary Extravascular Clearance (CL/F) of MEDI8897 Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Secondary Extravascular Volume of Distribution (Vz/F) of MEDI8897 Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Secondary Number of Participants Positive for Anti-Drug Antibodies to MEDI8897 A participant was considered ADA-positive if the participant had a positive reading at any time point post baseline. Titers greater than or equal to 50 were considered positive. Pre-dose at Baseline (Days -7 to -1) and on Days 31, 151, and 361 Post-dose
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04528719 - A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive Phase 1
Terminated NCT02508194 - A Study to Evaluate the Efficacy of MEDI7510 in Older Adults Phase 2
Active, not recruiting NCT06060457 - A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age Phase 3
Terminated NCT01757496 - Cough Assist in Bronchiolitis N/A
Completed NCT00100373 - RSV Challenge in Healthy Adults N/A
Completed NCT03524118 - Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Phase 1/Phase 2
Active, not recruiting NCT05572658 - Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
Recruiting NCT06067230 - A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults Phase 3
Completed NCT00246480 - RSV Disease in the Elderly
Active, not recruiting NCT06097299 - A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Phase 2
Completed NCT00889070 - Respiratory Events Among Premature Infants N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Completed NCT05559905 - Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Phase 2
Active, not recruiting NCT05127434 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age Phase 2/Phase 3
Terminated NCT04978337 - A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Phase 2
Recruiting NCT06143046 - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers Phase 2
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT02472548 - A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Phase 1
Completed NCT01562938 - MEDI-557 Adult Dosing Phase 1
Completed NCT01734668 - Sofia RSV FIA Field Study N/A